Afimetoran

DB16580InvestigationalSmall molecule

Afimetoran is an immunomodulator and an antagonist of toll-like receptors 7 and 8. It is also is under investigation in clinical trial NCT04269356 (Study to Assess the Way the Body...

Mechanism: Afimetoran acts as an antagonist of TLR 7/8.
Curator reviewed · 1 reference
Formula / weight: C₂₆H₃₂N₆O · 444.583 g/mol (avg)
Code names: BMS-986256

Resolves to

Compound

UNIILXP7MZL0VFCAS2171019-55-7

Structure

InChIKeySNFVHLQYHFQOEP-UHFFFAOYSA-NSMILESCC(C)C1=C(NC2=CC=C(C=C12)C1CCN(CC(N)=O)CC1)C1=CN2N=CN=C2C(C)=C1C

Targets

Q9NR97TLR8Q9NYK1TLR7

What you can answer from here — as of June 15, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

7Clinical trialsPhase, status and sponsor resolved per trial

8+ReferencesStructured and connected to the statements they support

Which drugs share a target with Afimetoran, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account